Last Posted: Sep 10, 2019
- Clinical lessons learned from the first leg of the CAR T cell journey
RJ Majzner et al, Nature Medicine, September 10, 2019 - Opportunities in Cancer Research: The Immune System and Microbiome
NCI 2021 annual plan, 2019 - Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.
Braun David A et al. JAMA oncology 2019 Sep - Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu Xue et al. JAMA network open 2019 Sep (9) e199292 - Potential impact of immunotherapy agents on cognitive function in cancer patients
F Joly et al, JNCI, August 2019 - Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer.
Doescher Johannes et al. Immunotherapy 2019 Aug - Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
S Ghorashian et al, Nature Medicine, September 2, 2019 - Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases
NCI, August 26, 2019 - Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
D Bomze et al, JAMA Oncology, August 22, 2019 - Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1
JS Lee et al, JAMA Oncology, August 22, 2019
.png)
No hay comentarios:
Publicar un comentario